{"slug":"ghrp-2","seoKey":"ghrp2","inn":"pralmorelin","displayName":"GHRP-2","codes":["KP-102","GPA-748"],"synonyms":["pralmorelin","pralmorelin hydrochloride","pralmorelin dihydrochloride","GHRP 2","GHRP2","growth hormone-releasing peptide 2","KP-102","KP-102D","KP-102LN","GPA-748","GHRP Kaken 100","pralmorelina","pralmoreline","pralmorelinum","D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2","approved as a prescription-only diagnostic medicine in Japan since 2004 (an eighth market the registry does not track)"],"legalClass":"rx","identifiers":{"cas":"158861-67-7","pubchemCid":6918245,"unii":"E6S6E1F19M","inchikey":"HRNLPPBUBKMZMT-RDRUQFPZSA-N","chemblId":"CHEMBL106593","wikidataQid":"Q21098924","formula":"C45H55N9O6","molecularWeight":818,"sequence":"D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved: no authorised medicine contains this substance, and a query of the agency's drug label database on 2026-09-10 returned no records for either the substance name or the abbreviation, while a control query for somatropin returned twenty-five labels in the same run. The substance is nonetheless the subject of an explicit agency decision: it sits in category 2 of the bulk substances that may present significant safety risks, added on 2023-09-29, for injectable and nasal routes, and under the outsourcing-facility section rather than the pharmacy-compounding one. The stated grounds are immunogenicity risk from aggregation and peptide-related impurities, an unnatural amino acid that complicates characterisation, and reports of serious adverse events including deaths of critically ill study subjects, infection and pancreatitis, with causality expressly not established. Development for a therapeutic indication reached phase 2 here under a licensee and appears to have been discontinued. Note that the substance is an authorised prescription medicine in Japan, a market this registry does not track, and there only as a single-dose diagnostic test for growth hormone deficiency.","date":"2023-09-29","source":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"market":"EU","status":"not_approved","note":"Not approved: no centrally authorised medicinal product. The finding is honest about its limits — the regulator's full-text search returned HTTP 401 from this environment on 2026-09-10 and could not be queried directly. It rests instead on the absence of any registration in every other register checked, on the absence of any European trade name across the literature, on a 2004 development register that records only unspecified licensing options for Europe and no pending application, and on a 2016 review stating that apart from the Japanese diagnostic approval no ghrelin receptor ligand has been successfully brought to market.","date":"2026-09-10","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=pralmorelin"},{"market":"DE","status":"not_approved","note":"Not approved on two levels. Under medicines law there is neither a centralised nor a national marketing authorisation, so no finished product containing the substance may be placed on the market, and the advertising restrictions for unauthorised medicines apply to any public-facing claim. Under anti-doping law the substance is named in the annex to section 2(3) of the anti-doping act, in part II.2.4 on peptides acting like growth hormone releasing factors: it is the first named example there, spelled out with its international nonproprietary name, followed by its glycine-extended form, GHRP-6, GHRP-6-Gly and hexarelin. Being listed under its own name is a qualitative difference from substances caught only by a catch-all clause.","date":"2026-09-10","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"Not approved: no marketing authorisation known, and unlicensed peptide preparations fall under the general rules for unauthorised medicines in the Human Medicines Regulations 2012. The finding is of limited depth — the regulator's product database answered with HTTP 200 on 2026-09-10 but returned only a client-rendered search shell without a server-side result list, so this is not backed by a register query of its own. No British trade name exists in any register checked.","date":"2026-09-10","source":"https://products.mhra.gov.uk/search/?search=pralmorelin"},{"market":"AU","status":"scheduled","date":"2026-05-28","note":"The strictest documented classification of any market here, quoted verbatim rather than inferred. The Poisons Standard carries the substance by name in Schedule 4 as a prescription-only poison, marked with a hash that denotes an additional Appendix D listing, and it appears again as item 30 in the Appendix D table, next to the collective entry for growth hormone releasing peptides at item 19. Appendix D clause 5 is headed poisons for which possession without authority is illegal. So this is not merely prescription-only: bare possession without authorisation is unlawful. No registered finished product is known, though the product register itself could not be reached on 2026-09-10 and that part is an assessment rather than a register finding.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not approved: the active-ingredient query of the drug product database returned an empty response on 2026-09-10, while a control query for somatropin in the same run returned several entries. The historical context is worth noting — the Japanese originator sublicensed the rights for both this market and the United States, and no authorisation followed in either.","date":"2026-09-10","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=pralmorelin"},{"market":"CH","status":"not_approved","note":"Not approved: no marketing authorisation known. The finding is of limited depth — the medicines information platform answered with HTTP 200 but served only a client-rendered shell without searchable content on 2026-09-10, and the regulator's overview page for authorised medicines returned HTTP 404, so no register could be queried directly. It is therefore an inference from the worldwide absence of any authorisation outside Japan and from the absence of a Swiss trade name. Independently of that, distributing or brokering unauthorised medicinal products is unlawful in this market.","date":"2026-09-10","source":"https://www.swissmedicinfo.ch/"}],"devStage":"approved","strongestEvidence":"rct_phase2","wada":{"status":"prohibited","section":"S2.2.4","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://www.wikidata.org/wiki/Q21098924","https://pubchem.ncbi.nlm.nih.gov/compound/6918245","https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL106593/","https://www.kegg.jp/entry/D02040"],"lastVerified":"2026-09-10","version":"1.0","published":true,"locale":"en","title":"GHRP-2: what the studies show, status and safety","summary":"GHRP-2 is a lab-made peptide that makes the pituitary gland release growth hormone. Japan licensed it in 2004, the only licence this family of peptides has, and it covers one injection used to test for a deficiency, not a treatment. The attempt to make a treatment of it stopped in phase 2. It is named on the world anti-doping list.","updated":"2026-09-10","url":"https://mypep.app/peptides/ghrp-2"}